Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
复制标题
DOI：
10.1038/sj.bjc.6603665
复制
发表时间：
2007-03-26
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
非小细胞肺癌患者亚群对表皮生长因子受体（EGFR）特异性小分子酪氨酸激酶抑制剂（TKI）如吉非替尼或厄洛替尼的反应非常好。2004年，发现激酶结构域中发生的EGFR突变与EGFR-TKI敏感性密切相关。然而，随后的研究表明，这种关系并不完美，并且已经报道了各种预测标志物。这些包括EGFR基因拷贝数、EGFR配体状态、EGFR下游其他HER家族基因或分子（包括KRAS或AKT）的变化。在这篇综述中，我们想回顾EGFR-TKI预测因素的现有知识。由于除一项III期试验外，所有III期试验均未显示EGFR-TKI治疗组的生存优势，因此有必要在未来的临床试验中通过这些生物标志物选择患者。通过这些努力，有可能为肺癌患者提供个性化的EGFR-TKI治疗。
Subsets of patients with non-small cell lung cancer respond remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib. In 2004, it was found that EGFR mutations occurring in the kinase domain are strongly associated with EGFR-TKI sensitivity. However, subsequent studies revealed that this relationship was not perfect and various predictive markers have been reported. These include EGFR gene copy numbers, status of ligands for EGFR, changes in other HER family genes or molecules downstream to EGFR including KRAS or AKT. In this review, we would like to review current knowledge of predictive factors for EGFR-TKI. As all but one phase III trials failed to show a survival advantage of the treatment arm involving EGFR-TKIs, it is necessary to select patients by these biomarkers in future clinical trials. Through these efforts, it would be possible to individualise EGFR-TKI treatment for patients suffering from lung cancer.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
45.3
作者：
Eberhard, DA;Johnson, BE;Hillan, KJ
通讯作者：
Hillan, KJ
影响因子：
158.5
作者：
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者：
Halmos, B
影响因子：
15.8
作者：
Greulich H;Chen TH;Feng W;Jänne PA;Alvarez JV;Zappaterra M;Bulmer SE;Frank DA;Hahn WC;Sellers WR;Meyerson M
通讯作者：
Meyerson M
影响因子：
45.3
作者：
Mitsudomi, T;Kosaka, T;Yatabe, Y
通讯作者：
Yatabe, Y